Science Exchange, a Palo Alto, CA-based marketplace for scientific research, raised $25m in Series B funding.
The round was led by Maverick Capital Ventures with participation from Union Square Ventures, Index Ventures, YC Continuity Fund, Sam Altman, and others. As part of the round, Maverick Capital Ventures Managing Partner David Singer (former Founder/CEO of Affymetrix, GeneSoft Pharmaceuticals, and Corcept Therapeutics) will join Science Exchange’s board.
The company intends to use the funds to expand its team in all areas including product, engineering, sales, marketing, and customer success.
Founded in 2011 by Dr. Elizabeth Iorns, CEO, Science Exchange is a marketplace for scientific research services. The company provides secure access to a network of 1000s of screened and verified contract research organizations (CROs), academic labs, and government facilities that are available to conduct experiments on the behalf of scientists. The platform has been used by scientists from over 2,500 different companies and organizations, including many large pharmaceutical companies.